Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OCUP Ocuphire Pharma		$1.26	$1.07 ▼ $3.40	$30.33M	0.2	171,840 shs	676,700 shs
PYRGF PyroGenesis Canada	$0.28 +4.2%	$0.33	$0.25 ▼ $0.71	$51.76M	0.83	12,804 shs	10,675 shs
VIRI Virios Therapeutics	$4.77 -2.5%	$4.86	$0.13 ▼ $1.04	$91.86M	1.58	1.05 million shs	7,788 shs
WHWK Whitehawk Therapeutics	$1.74 +3.0%	$0.00	$1.37 ▼ $3.81	$82.01M	0.55	151,345 shs	80,668 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OCUP Ocuphire Pharma	0.00%	0.00%	0.00%	0.00%	-29.94%
PYRGF PyroGenesis Canada	-5.39%	-9.03%	-20.78%	-19.75%	-53.63%
VIRI Virios Therapeutics	0.00%	+0.82%	+2.73%	+2.30%	+2,702.29%
WHWK Whitehawk Therapeutics	-3.43%	-3.98%	-11.52%	+168,999,900.00%	+168,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	0.3147 of 5 stars	0.0	4.0	0.0	0.0	0.0	1.7	0.0
VIRI Virios Therapeutics	0.112 of 5 stars	1.0	0.0	0.0	0.0	0.0	0.8	0.6
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OCUP Ocuphire Pharma	3.00	Buy	$14.00	∞ Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A
VIRI Virios Therapeutics	2.00	Hold	$5.00	4.82% Upside
WHWK Whitehawk Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OCUP Ocuphire Pharma	$16.45M	0.00	N/A	N/A	$2.20 per share	0.00
PYRGF PyroGenesis Canada	$9.14M	5.66	N/A	N/A	($0.01) per share	-27.60
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A
WHWK Whitehawk Therapeutics	$25.98M	3.16	N/A	N/A	$2.12 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OCUP Ocuphire Pharma	-$9.99M	-$0.49	N/A	N/A	N/A	-85.75%	-30.19%	-27.55%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.03	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A
WHWK Whitehawk Therapeutics	-$63.69M	-$0.06	N/A	∞	N/A	99.42%	-75.99%	-68.57%	N/A

Latest OCUP, VIRI, WHWK, and PYRGF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	WHWK Whitehawk Therapeutics	$0.49	-$0.76	-$1.25	-$0.76	$100.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OCUP Ocuphire Pharma	N/A	10.68	10.68
PYRGF PyroGenesis Canada	N/A	0.60	0.50
VIRI Virios Therapeutics	N/A	7.27	7.27
WHWK Whitehawk Therapeutics	N/A	20.41	20.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OCUP Ocuphire Pharma	14.97%
PYRGF PyroGenesis Canada	0.03%
VIRI Virios Therapeutics	9.05%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
OCUP Ocuphire Pharma	8.70%
PYRGF PyroGenesis Canada	47.68%
VIRI Virios Therapeutics	12.20%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OCUP Ocuphire Pharma	14	25.92 million	24.47 million	Optionable
PYRGF PyroGenesis Canada	90	187.53 million	96.34 million	No Data
VIRI Virios Therapeutics	5	19.26 million	16.91 million	Optionable
WHWK Whitehawk Therapeutics	40	47.13 million	23.61 million	N/A

OCUP, VIRI, WHWK, and PYRGF Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) Rating Lowered to Strong Sell at Wall Street Zen

August 11 at 2:59 AM | americanbankingnews.com

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Misses Expectations By $1.25 EPS

August 10 at 12:37 AM | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 10 at 2:36 AM | marketbeat.com

Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

August 7, 2025 | prnewswire.com

Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 22, 2025 | prnewswire.com

Media Sentiment Over Time

OCUP, VIRI, WHWK, and PYRGF Company Descriptions

Ocuphire Pharma NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

PyroGenesis Canada NASDAQ:PYRGF

$0.28 +0.01 (+4.19%)

As of 02:36 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

Virios Therapeutics NASDAQ:VIRI

$4.77 -0.12 (-2.45%)

As of 08/11/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Whitehawk Therapeutics NASDAQ:WHWK

$1.74 +0.05 (+2.96%)

As of 03:07 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time